(NASDAQ: AVTX) Avalo Therapeutics's forecast annual revenue growth rate of 31.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Avalo Therapeutics's revenue in 2025 is $441,000.On average, 1 Wall Street analysts forecast AVTX's revenue for 2029 to be $478,580,804, with the lowest AVTX revenue forecast at $478,580,804, and the highest AVTX revenue forecast at $478,580,804. On average, 3 Wall Street analysts forecast AVTX's revenue for 2030 to be $1,639,442,427, with the lowest AVTX revenue forecast at $77,525,759, and the highest AVTX revenue forecast at $3,552,325,570.
In 2031, AVTX is forecast to generate $3,779,164,209 in revenue, with the lowest revenue forecast at $697,948,385 and the highest revenue forecast at $6,860,380,032.